- Home
- OSRH vs BOLT Comparison
OSRH vs BOLT Comparison
Compare OSRH & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSRH | BOLT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 10.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OSRH | BOLT |
|---|---|---|
| Price | $0.71 | $4.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 1.2M | 24.9K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.38 | $0.26 |
| 52 Week High | $1.79 | $7.35 |
Technical Indicators
Market Signals| Indicator | OSRH | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 50.52 |
| Support Level | $0.47 | $4.27 |
| Resistance Level | $0.70 | $5.22 |
| Average True Range (ATR) | 0.11 | 0.44 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 56.71 | 24.19 |
Price Performance
Historical ComparisonAbout OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.